pLenti CMV-MRLC1-mRuby2-IRES-PuroR
(Plasmid
#103031)
-
PurposeLentiviral expression of mRuby2-tagged MRLC with puromycin selection
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 103031 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepCIG3 #78264
-
Backbone manufacturerGoodrum Lab, University of Arizona
- Backbone size w/o insert (bp) 8161
- Total vector size (bp) 8677
-
Modifications to backboneSubcloned in Puromycin resistance gene in place of GFP behind the IRES sequence
-
Vector typeLentiviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature30°C
-
Growth Strain(s)NEB Stable
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert nameMRLC1
-
Alt nameMYL9
-
SpeciesH. sapiens (human)
-
Insert Size (bp)516
-
GenBank IDNM_006097.4
-
Entrez GeneMYL9 (a.k.a. LC20, MLC-2C, MLC2, MMIHS4, MRLC1, MYRL2)
- Promoter CMV immediate early
-
Tag
/ Fusion Protein
- mRuby2 (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BamHI (not destroyed)
- 3′ cloning site AgeI (not destroyed)
- 5′ sequencing primer CMV Forward
- 3′ sequencing primer IRES-R (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byTom Egelhoff, Addgene #35680
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLenti CMV-MRLC1-mRuby2-IRES-PuroR was a gift from Ghassan Mouneimne (Addgene plasmid # 103031 ; http://n2t.net/addgene:103031 ; RRID:Addgene_103031) -
For your References section:
The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. Padilla-Rodriguez M, Parker SS, Adams DG, Westerling T, Puleo JI, Watson AW, Hill SM, Noon M, Gaudin R, Aaron J, Tong D, Roe DJ, Knudsen B, Mouneimne G. Nat Commun. 2018 Jul 30;9(1):2980. doi: 10.1038/s41467-018-05367-2. 10.1038/s41467-018-05367-2 [pii] PubMed 30061623